Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lyell Immunopharma filings document the regulatory record of a Nasdaq-listed clinical biotechnology company developing next-generation CAR T-cell therapies. Its 8-K reports furnish operating results and business updates for ronde-cel in large B-cell lymphoma and LYL273 in metastatic colorectal cancer and other GCC-expressing cancers, along with cash, financing and clinical-program disclosures.
The company’s filings also cover material agreements, including licensing rights for LYL273, and governance matters such as annual-meeting proposals, director elections, auditor ratification, executive compensation votes, officer appointments and compensatory arrangements. Securities disclosures identify Lyell’s common stock listed on the Nasdaq Global Select Market.
Lyell Immunopharma (LYEL) reported Q3 2025 results highlighted by continued R&D investment, a narrowed quarterly loss, and a mid‑year capital raise. The company recorded revenue of $15 thousand and a net loss of $38.8 million, improving from a $44.6 million loss a year ago. Operating expenses were $37.3 million, with research and development at $28.2 million and general and administrative at $10.7 million. Interest income contributed $3.3 million. Year‑to‑date, net loss was $133.7 million.
Liquidity remained strong. Cash and cash equivalents were $123.6 million and marketable securities were $196.0 million as of September 30, 2025, for total current liquid investments of $319.6 million. Net cash used in operating activities was $117.8 million for the nine months. In July, the company raised $50.0 million by issuing 3,753,752 shares at $13.32 per share under a Securities Purchase Agreement and recognized a related SPA put/call asset. A 1‑for‑20 reverse stock split was effected on May 30, 2025. Shares outstanding were 19,294, as of quarter‑end, and 21,218,217 as of November 10, 2025.
The company issued 625,000 shares valued at $5.9 million upon achieving an ImmPACT milestone. It also recorded a $1.4 million impairment tied to closing its West Hills facility after transitioning manufacturing to its LyFE center in Bothell, WA.
Lyell Immunopharma, Inc. furnished an update on its financial results for the quarter ended September 30, 2025 via a Form 8‑K. The company attached a press release as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished, not filed, and is therefore not subject to Section 18 liabilities and is not incorporated by reference except as specifically stated.
Lyell Immunopharma (LYEL) filed an initial statement of beneficial ownership for its VP, Corporate Controller, effective 10/31/2025. The reporting person holds 9,452 shares of common stock directly, which includes RSUs subject to time-based vesting beginning after August 9, 2025. They also hold stock options to purchase 1,674, 624, and 3,000 shares at exercise prices of $42.6 and $37.4, expiring on 02/23/2033, 03/15/2032, and 09/09/2031, respectively, with noted vesting schedules.
Lyell Immunopharma (LYEL) signed an Exclusive License Agreement with Innovative Cellular Therapeutics, gaining rights to research, develop, manufacture and commercialize certain cell therapy candidates worldwide except mainland China, Taiwan, Macau and Hong Kong. In return, Lyell will pay $40 million in cash and issue 1.9 million common shares to ICT Holdings.
The deal includes meaningful performance-based economics: a potential $30 million clinical milestone, up to $115 million in late-stage regulatory milestones, and up to $675 million in commercial sales milestones, plus up to an additional 1.85 million shares upon certain clinical and regulatory milestones. Tiered royalties apply, ranging from mid-single digits up to 10% on U.S. net sales and low to mid-single digits elsewhere in the licensed territory.
Lyell also entered a Registration Rights Agreement to provide ICT Holdings with shelf registration for the resale of shares issuable under the license. The securities were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act.
Lyell Immunopharma (LYEL) announced leadership changes in its finance function. On October 31, 2025, the Board appointed CEO Lynn Seely, M.D., as interim principal financial officer and named Veronica Sanchez Bulis as principal accounting officer.
Bulis has served as Vice President, Corporate Controller since August 2021 and previously held senior finance roles at Sangamo Therapeutics (2018–2021) and Core-Mark International (2008–2018), with earlier public accounting experience at Ernst & Young and Deloitte.
Lyell Immunopharma (LYEL) reported insider activity by its Chief Operating Officer via Form 4. On 10/27/2025, the officer received an option to buy 75,000 shares of common stock at an exercise price of $17.23. The award vests with 12.5% of the option shares on April 27, 2026, and the remainder in equal monthly installments over the following 42 months, subject to continued service. Following the reported transactions, the officer beneficially owned 15,845 shares of common stock, held directly.
Lyell Immunopharma (LYEL) reported an insider equity award. The company’s Chief Scientific Officer filed a Form 4 showing an option grant for 68,000 shares with an exercise price of $17.23 on 10/27/2025. These options expire on 10/26/2035.
Vesting is staged: 12.5% vests on 4/27/2026, with the remainder vesting in equal monthly installments over the following 42 months, contingent on continued service. Following the reported transactions, the insider reported 15,504 shares of common stock beneficially owned, held directly.
Lyell Immunopharma (LYEL) reported an insider equity award. The reporting person, who serves as President, CEO and Director, acquired 175,000 stock options on 10/27/2025 at an exercise price of $17.23, expiring on 10/26/2035.
Vesting is scheduled with 12.5% on April 27, 2026, and the remainder in equal monthly installments over the following 42 months, subject to continued service. Following the reported transactions, the insider beneficially owns 67,571 shares of common stock.
Lyell Immunopharma, Inc. reported that Chief Financial Officer Charles Newton, who also serves as the company’s principal financial and accounting officer, has decided to resign. His resignation will be effective October 31, 2025. The company states there were no disagreements between Mr. Newton and Lyell.
Lyell plans to conduct a search for a new CFO to take over its financial leadership. To support continuity, the company and Mr. Newton entered into a consulting agreement under which he may provide consulting services from the resignation date through April 30, 2026, unless either party ends the consultancy earlier.
Seely Lynn, who serves as President and CEO and a director of Lyell Immunopharma, reported the issuance and a subsequent sale of company common stock. Per performance-based restricted stock units granted on February 9, 2024, 40,000 shares were recorded as issued on 08/20/2025, with 20,000 shares issued immediately upon certification of performance and the remaining 20,000 shares scheduled for issuance on 08/20/2026 subject to continued service. The next day, 7,257 shares were sold automatically to cover tax withholding at a weighted average price of $10.544 (sales ranged $10.49 to $10.64). After these transactions the reporting person beneficially owned 67,571 shares.